These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1233253)

  • 1. On the fate of furosemide in man.
    Beermann B; Dalén E; Lindström B; Rosén A
    Eur J Clin Pharmacol; 1975 Oct; 9(1):51-61. PubMed ID: 1233253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biotransformation of furosemide in kidney transplant patients.
    Smith DE; Benet LZ
    Eur J Clin Pharmacol; 1983; 24(6):787-90. PubMed ID: 6350024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elimination of furosemide in healthy subjects and in those with renal failure.
    Beermann B; Dalén E; Lindström B
    Clin Pharmacol Ther; 1977 Jul; 22(1):70-8. PubMed ID: 872498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the absorption and metabolism of 35S-ampicillin.
    Swahn A
    Eur J Clin Pharmacol; 1975 Dec; 9(2-3):117-24. PubMed ID: 1233260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biotransformation of furosemide in patients with acute pulmonary edema.
    Perez J; Sitar DS; Ogilvie RI
    Drug Metab Dispos; 1979; 7(6):383-7. PubMed ID: 43224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure.
    Ogata H; Kawatsu Y; Maruyama Y; Machida K; Haga T
    Eur J Clin Pharmacol; 1985; 28(1):53-9. PubMed ID: 3987786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the metabolism of meptazinol, a new analgesic drug.
    Franklin RA; Aldridge A
    Br J Clin Pharmacol; 1976 Jun; 3(3):497-502. PubMed ID: 973975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis.
    Hammarlund MM; Paalzow LK; Odlind B
    Eur J Clin Pharmacol; 1984; 26(2):197-207. PubMed ID: 6723758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay.
    Smith DE; Lin ET; Benet LZ
    Drug Metab Dispos; 1980; 8(5):337-42. PubMed ID: 6107232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption, distribution, metabolism, and excretion of furosemide in dogs and monkeys I: analytical methodology, metabolism, and urinary excretion.
    Yakatan GJ; Maness DD; Scholler J; Novick WJ; Doluisio JT
    J Pharm Sci; 1976 Oct; 65(10):1456-60. PubMed ID: 824434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition and absolute bioavailability of furosemide in healthy males.
    Waller ES; Hamilton SF; Massarella JW; Sharanevych MA; Smith RV; Yakatan GJ; Doluisio JT
    J Pharm Sci; 1982 Oct; 71(10):1105-8. PubMed ID: 7143205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of furosemide in patients with congestive heart failure.
    Greither A; Goldman S; Edelen JS; Benet LZ; Cohn K
    Pharmacology; 1979; 19(3):121-31. PubMed ID: 523503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Furosemide kinetics in renal failure.
    Tilstone WJ; Fine A
    Clin Pharmacol Ther; 1978 Jun; 23(6):644-50. PubMed ID: 648078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cimetidine on the absorption and efficacy of orally administered furosemide.
    Rogers HJ; Morrison P; House FR; Bradbrook ID
    Int J Clin Pharmacol Ther Toxicol; 1982 Jan; 20(1):8-11. PubMed ID: 7056605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism.
    Lee MG; Chiou WL
    J Pharmacokinet Biopharm; 1983 Dec; 11(6):623-40. PubMed ID: 6678312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of HPLC to elucidate the metabolism and urinary excretion of furosemide and its metabolic products.
    Andreasen F; Christensen CK; Jakobsen FK; Mogensen CE
    Acta Pharmacol Toxicol (Copenh); 1981 Sep; 49(3):223-9. PubMed ID: 7336980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of furosemide urinary elimination by nephrotic children.
    Prandota J
    Pediatr Res; 1983 Feb; 17(2):141-7. PubMed ID: 6828331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of orally administered furosemide.
    Kelly MR; Cutler RE; Forrey AW; Kimpel BM
    Clin Pharmacol Ther; 1974 Feb; 15(2):178-86. PubMed ID: 4812154
    [No Abstract]   [Full Text] [Related]  

  • 19. Implications of intraindividual variability in bioavailability studies of furosemide.
    Grahnén A; Hammarlund M; Lundqvist T
    Eur J Clin Pharmacol; 1984; 27(5):595-602. PubMed ID: 6519165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma and tissue levels of furosemide in dogs and monkeys following single and multiple oral doses.
    Yakatan GJ; Maness DD; Scholler J; Johnston JT; Novick WJ; Doluisio JT
    Res Commun Chem Pathol Pharmacol; 1979 Jun; 24(3):465-82. PubMed ID: 109903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.